3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
8
Breast
4
Gastrointestinal
3
Head & Neck
2
Genitourinary
2
Thoracic
1
CNS
1
Conditions
Thyroid Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
8
Thyroid Carcinoma, Anaplastic
5
Thyroid Cancer, Papillary
3
Endometrial Neoplasms
3
Adenocarcinoma, Follicular
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Cancer Metastatic
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Differentiated Thyroid Cancer (DTC)
1
Interventions
pembrolizumab
28
Nivolumab
13
Carboplatin
9
fludarabine
7
Paclitaxel
7
Gemcitabine
7
Docetaxel
7
Cyclophosphamide
7
Cisplatin
7
Trastuzumab
5
palbociclib
4
cemiplimab
4
avelumab
4
atezolizumab
4
Ipilimumab
4
Fluorouracil
4
Filgrastim
4
Drug Therapy
4
Cetuximab
4
fludarabine phosphate
3
epacadostat
3
durvalumab
3
Taxes
3
Oxaliplatin
3
Fulvestrant
3
zimberelimab
2
ulixertinib
2
trametinib
2
tisotumab vedotin
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
lenvatinib
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled